Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128296 | 1.00 | MEN1 (0.48) | MEN1KMT2APOLBNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29356681 | 0.99 | MEN1 (0.47) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL15397117 | 0.93 | MEN1 (0.43) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL18680529 | 0.90 | MEN1 (0.50) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL23675025 | 0.89 | APP (0.40) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL18070566 | 0.89 | MEN1 (0.47) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL12364541 | 0.89 | MEN1 (0.47) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL15215399 | 0.89 | APAF1 (0.44) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL20329155 | 0.89 | MEN1 (0.39) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL14294136 | 0.89 | MEN1 (0.45) | MEN1KMT2APOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142726-B | Anti-tumor drug hydrochloride hydrate crystal form | 上海汇伦医药股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-116143964-A | Monodisperse superparamagnetism fluorescent coding microsphere, preparation method and application | N科研中心私人投资有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-109843885-B | Medicinal salt of antineoplastic heterocyclic imidazole compound | 上海汇伦生物科技有限公司 | 2022-03-29 | — | — | CN | claimed |
| US-12637489-B2 | Silicon containing modified nucleotide analogs | Singular Genomics Systems, Inc. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630808-B2 | Modified archaeal family b polymerases | Singular Genomics Systems, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260110028-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12595508-B2 | Nucleotide cleavable linkers and uses thereof | Singular Genomics Systems, Inc. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4713477-A1 | DETECTION OF TARGET ANALYTES USING MULTIMODAL SIGNAL PROBES | Roche Molecular Systems, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | Viradem, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20220119780-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| US-20220119779-A1 | MODIFIED PYROCOCCUS POLYMERASES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2022-04-21 | — | — | US | disclosed |
| WO-2022072374-A1 | LIGHT-CONTROLLED BIOORTHOGONAL TETRAZINE LIGATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20220098652-A1 | NICKING AND EXTENSION AMPLIFICATION REACTION (NEAR) OF STREPTOCOCCUS SPECIES | IONIAN TECHNOLOGIES, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3974412-A1 | RAPID FLUORESCENCE TAGGING OF GLYCANS AND OTHER BIOMOLECULES WITH ENHANCED MS SIGNALS | Waters Technologies Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-109843885-B | Medicinal salt of antineoplastic heterocyclic imidazole compound | 上海汇伦生物科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-109843885-B | Medicinal salt of antineoplastic heterocyclic imidazole compound | 上海汇伦生物科技有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11279982-B2 | EGFR assay | ABBOTT MOLECULAR INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11266673-B2 | Nucleotide derivatives and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630808-B2 | Modified archaeal family b polymerases | SSU72, POLB, POLQ | MEN1 3513/4885KMT2A 308/4885POLB 2/4885 |
| US-12595508-B2 | Nucleotide cleavable linkers and uses thereof | NSUN2, CCRL2, NOP2 | MEN1 4378/4885KMT2A 2804/4885POLB 160/4885 |
| US-12637489-B2 | Silicon containing modified nucleotide analogs | NSUN2, POLR2H, POLH | MEN1 2394/4885KMT2A 2375/4885POLB 7/4885 |
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | ACE2, ACE, SARS1 | MEN1 4492/4885KMT2A 2023/4885POLB 2065/4885 |
| US-20260110028-A1 | NUCLEOTIDE ANALOGS AND USES THEREOF | POLL, POLB, POLN | MEN1 3638/4885KMT2A 1209/4885POLB 2/4885 |
| US-20260085299-A1 | ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF | POLB, POLM, POLRMT | MEN1 1571/4885KMT2A 1696/4885POLB 1/4885 |
| US-20260125660-A1 | MODIFIED ARCHAEAL FAMILY B POLYMERASES | DNMT3A, POLB, POLM | MEN1 2077/4885KMT2A 755/4885POLB 2/4885 |
| US-11266673-B2 | Nucleotide derivatives and methods of use thereof | POLRMT, NSUN2, NUDT1 | MEN1 3223/4885KMT2A 1863/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.